Torbjørn Furuseth joins Targovax as CFO

Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovaxs CFO, will become Chief Business Officer, replacing Michael Bogenstaetter